Rahko’s Co-founder and former VP of AI at Odyssey Therapeutics will lead the technical growth of LabGenius’ ML-driven drug discovery platform LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use ...

LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use of machine learning (ML) for antibody engineering, today announced that it has been awarded a highly competitive SMART grant from Innovate UK.

Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVA TM, to the optimization of therapeutic NANOBODY ® proteins LONDON–(BUSINESS WIRE)–July 15, 2021– ...

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™,was used to discover and concomitantly optimise a TCE with improved killing ...

LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) Annual 2023 Meeting ...

The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for ...

LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize complex therapeutic antibodies, including those with ...

Innovate UK, part of UK Research and Innovation (UKRI), has awarded LabGenius with a SMART grant to accelerate the development of its immune cell engager lead optimization capability LONDON–(BUSINESS ...